High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome
| Autor: | Iosif Strouthos, Efstratios Karagiannis, Nikolaos Zamboglou, Konstantinos Ferentinos |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
interstitial brachytherapy Cancer Research medicine.medical_specialty medicine.medical_treatment Brachytherapy Review Radiosurgery Prostate cancer Risk groups salvage Prostate medicine Humans Medical physics RC254-282 Dose delivery business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens Prostatic Neoplasms prostate cancer medicine.disease High-Dose Rate Brachytherapy medicine.anatomical_structure Clinical research Oncology monotherapy combined with EBRT Dose Fractionation Radiation business high‐dose‐rate |
| Zdroj: | Cancer Reports Cancer Reports, Vol 5, Iss 1, Pp n/a-n/a (2022) |
| ISSN: | 2573-8348 |
| DOI: | 10.1002/cnr2.1450 |
| Popis: | Background High‐dose‐rate brachytherapy (HDR BRT) has been enjoying rapid acceptance as a treatment modality offered to selected prostate cancer patients devoid of risk group, employed either in monotherapy setting or combined with external beam radiation therapy (EBRT) and is currently one of the most active clinical research areas. Recent findings This review encompasses all the current evidence to support the use of HDR BRT in various clinical scenario and shines light to the HDR BRT rationale, as an ultimately conformal dose delivery method enabling safe dose escalation to the prostate. Conclusion Valid long‐term data, both in regard to the oncologic outcomes and toxicity profile, support the current clinical indication spectrum of HDR BRT. At the same time, this serves as solid, rigid ground for emerging therapeutic applications, allowing the technique to remain in the spotlight alongside stereotactic radiosurgery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text